Lantern Pharma Enters Pivotal Phase with AI Commercialization and Advancing Clinical Trials

Lantern Pharma marked a pivotal Q1 2025 with accelerated clinical progress, including expected full enrollment of its LP-184 trial by June, and the upcoming commercialization of its radar AI platform—starting with a blood-brain barrier prediction tool—positioning the company at the intersection of precision oncology and AI-driven drug development.